DC Investments Management’s TScan Therapeutics TCRX Stock Holding History

DC Investments Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.9K	Hold	35,563	–	–	0.01%	55
2026 Q1	$35.9K	Hold	35,563	–	–	0.01%	76
2025 Q4	$35.6K	Hold	35,563	–	–	0.02%	48
2025 Q3	$64.7K	Hold	35,563	–	–	0.03%	95
2025 Q2	$51.6K	Hold	35,563	–	–	0.02%	104
2025 Q1	$49.1K	Hold	35,563	–	–	0.03%	110
2024 Q4	$108K	Hold	35,563	–	–	0.07%	89
2024 Q3	$177K	Hold	35,563	–	–	0.12%	84
2024 Q2	$208K	Hold	35,563	–	–	0.18%	80
2024 Q1	$282K	Hold	35,563	–	–	0.23%	84
2023 Q4	$207K	Hold	35,563	–	–	0.21%	73
2023 Q3	$91K	Hold	35,563	–	–	0.11%	83
2023 Q2	$88.9K	Hold	35,563	–	–	0.1%	81
2023 Q1	$74.7K	Hold	35,563	–	–	0.09%	82
2022 Q4	$55.1K	Hold	35,563	–	–	0.07%	58
2022 Q3	$110K	Hold	35,563	–	–	0.25%	27
2022 Q2	$112K	Hold	35,563	–	–	0.25%	36
2022 Q1	$100K	Hold	35,563	–	–	0.17%	46
2021 Q4	$160K	Hold	35,563	–	–	0.23%	54
2021 Q3	$297K	Buy	+35,563	New	+$330K	0.55%	41

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

DC Investments Management's TCRX Position: Q2 2026 in Review

DC Investments Management held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 35,563 shares worth $34.9K. The position accounts for 0.01% of the portfolio, ranked #55.

DC Investments Management first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $297K in Q3 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

DC Investments Management held 35,563 shares of TScan Therapeutics worth $34.9K as of Q2 2026.
DC Investments Management left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up 0.01% of DC Investments Management's portfolio in Q2 2026, its #55 holding.
DC Investments Management first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
DC Investments Management's TScan Therapeutics position peaked at $297K in Q3 2021.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on DC Investments Management's 13F filing for Q2 2026, filed 14 Aug 2026.